| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013164393 |
| P356 | DOI | 10.1038/SJ.BJC.6603925 |
| P932 | PMC publication ID | 2360360 |
| P698 | PubMed publication ID | 17726450 |
| P5875 | ResearchGate publication ID | 6114782 |
| P2093 | author name string | J H M Schellens | |
| S Marchetti | |||
| P2860 | cites work | The price of innovation: new estimates of drug development costs | Q28212140 |
| The value of improving the productivity of the drug development process: faster times and better decisions | Q28216310 | ||
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| Combinatorial chemistry in cancer drug development. | Q34195838 | ||
| Preclinical pharmacokinetics: an approach towards safer and efficacious drugs | Q34493518 | ||
| PET for in vivo pharmacokinetic and pharmacodynamic measurements | Q34974991 | ||
| Clinical trial design for target-based therapy | Q34981120 | ||
| Big physics, small doses: the use of AMS and PET in human microdosing of development drugs | Q35075780 | ||
| Improved early clinical development through human microdosing studies | Q36182266 | ||
| Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies | Q36466906 | ||
| Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. | Q36751567 | ||
| Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs | Q48665583 | ||
| Compressing drug development timelines in oncology using phase '0' trials | Q53208031 | ||
| Response rates, duration of response, and dose response effects in phase I studies of antineoplastics | Q67899179 | ||
| Risks in new drug development: approval success rates for investigational drugs | Q73924789 | ||
| Slow start to phase 0 as researchers debate value | Q79760785 | ||
| Less is more: the human microdosing concept | Q81611248 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomedical investigative technique | Q66648976 |
| P304 | page(s) | 577-581 | |
| P577 | publication date | 2007-08-28 | |
| 2007-09-03 | |||
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials | |
| P478 | volume | 97 |
| Q26801794 | 68Ga-Based radiopharmaceuticals: production and application relationship |
| Q95851906 | A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug |
| Q94546994 | A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs |
| Q40786849 | A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine |
| Q59307351 | Biocompatibility evaluation of self-assembled micelles prepared from poly(lactide-co-glycolide)-poly(ethylene glycol) diblock copolymers |
| Q58158341 | Biomedical Conventions and Regulatory Objectivity |
| Q30394673 | Biomedical Imaging in Implantable Drug Delivery Systems |
| Q56430923 | Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics |
| Q36205561 | Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy |
| Q49280135 | Comparative oncology: Integrating human and veterinary medicine |
| Q30406342 | Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. |
| Q27022324 | Designing Safer and Greener Antibiotics |
| Q35195500 | Development of radiotracers for oncology--the interface with pharmacology |
| Q26752713 | Diagnostics based on nucleic acid sequence variant profiling: PCR, hybridization, and NGS approaches |
| Q37922776 | Discontinued drugs in 2010: cardiovascular drugs |
| Q57806452 | Dose translation between laboratory animals and human in preclinical and clinical phases of drug development |
| Q46711980 | Enhancing the Alignment of the Preclinical and Clinical Stroke Recovery Research Pipeline: Consensus-Based Core Recommendations From the Stroke Recovery and Rehabilitation Roundtable Translational Working Group |
| Q45959205 | Enhancing the alignment of the preclinical and clinical stroke recovery research pipeline: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable translational working group. |
| Q41083360 | Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging |
| Q41906250 | Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A |
| Q34977050 | Imaging and cancer: a review |
| Q46531595 | In Silico Models for Repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for Drugs |
| Q27000792 | Lost in translation: animal models and clinical trials in cancer treatment |
| Q37964571 | Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials |
| Q37810237 | Microdosing: Current and The Future |
| Q39572657 | Nanoparticle Therapeutics: FDA Approval, Clinical Trials, Regulatory Pathways, and Case Study |
| Q37152009 | Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. |
| Q37358492 | Novel clinical trial designs for innovative therapies |
| Q36732058 | Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient |
| Q38749909 | Overview of the Use of Murine Models in Leukemia and Lymphoma Research. |
| Q90360263 | Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents |
| Q90211749 | Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients |
| Q35602195 | Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva. |
| Q34941964 | Phase 0 clinical trials in oncology new drug development |
| Q37184280 | Phase 0 clinical trials: conceptions and misconceptions |
| Q84400479 | Phase 0 exploratory clinical trials: literature review 2006-2009 |
| Q92867685 | Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose |
| Q36480084 | Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors |
| Q37675456 | Predictive toxicology approaches for small molecule oncology drugs |
| Q38810472 | Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing's sarcoma. |
| Q37435222 | Prospective of ⁶⁸Ga-radiopharmaceutical development |
| Q38084156 | Prospects of Nano–Material in Breast Cancer Management |
| Q37588057 | Radiosynthesis and pharmacokinetics of [18F]fluoroethyl bufalin in hepatocellular carcinoma-bearing mice |
| Q39934032 | Role of Phase 0 trials in drug development |
| Q45107461 | Sodium tungstate modulates ATM function upon DNA damage |
| Q38088802 | Systems biology of cyanobacterial secondary metabolite production and its role in drug discovery. |
| Q39769308 | The Role of Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling in Drug Discovery and Development |
| Q38734115 | The use of human neurons for novel drug discovery in dementia research. |
| Q26798118 | Translating clinical trials from human to veterinary oncology and back |
| Q37992702 | Using High-Resolution Quadrupole Tof Technology in Dmpk Analyses |
| Q37289389 | Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine |
Search more.